Pancreatic Cancer Research

ResearcherInstituto de Salud Carlos IIIActive in the last 2 years

Silvestre Vicent

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9457-6881; OpenAlex author ID A5045979459. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: none · 2025: 2 papers

Papers 9

  1. Quantitative evaluation of the role of the microenvironment in the phenotype, metabolism, and drug resistance of PDAC tumor organoids Co-author DOI 10.1101/2024.12.31.630904↗
  2. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03268-5↗
  3. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth. Last author DOI 10.1158/1078-0432.ccr-22-0794↗
  4. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer. Last author DOI 10.1186/s12943-023-01788-w↗
  5. Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer Last author DOI 10.1186/s12943-023-01795-x↗
  6. The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. Co-author DOI 10.1158/0008-5472.can-20-4263↗
  7. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem? First author DOI 10.3389/fcell.2021.787249↗
  8. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Last author DOI 10.1038/ncomms14294↗
  9. All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS. Last author DOI 10.1080/23723556.2017.1314239↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mariano Ponz‐Sarvisé · 5 shared papers, 2017–2025 · strength 0.83
  2. Shruthi Narayanan · 3 shared papers, 2021–2025 · strength 0.61
  3. Adrián Vallejo · 4 shared papers, 2017–2023 · strength 0.44
  4. Rodrigo Entrialgo‐Cadierno · 3 shared papers, 2023 · strength 0.41
  5. Oihane Erice · 3 shared papers, 2023 · strength 0.41
  6. Ioritz Sorzabal-Bellido · 1 shared paper, 2025 · strength 0.25
  7. Carlos Ortíz-de-Solórzano · 1 shared paper, 2025 · strength 0.25
  8. Daniel Oyón · 1 shared paper, 2025 · strength 0.17
  9. Giulia Orsi · 1 shared paper, 2025 · strength 0.17
  10. Maite G. Fernández‐Barrena · 1 shared paper, 2025 · strength 0.17
  11. Marija Trajkovic‐Arsic · 1 shared paper, 2023 · strength 0.14
  12. Vincenzo Corbo · 1 shared paper, 2023 · strength 0.14
  13. Pietro Delfino · 1 shared paper, 2023 · strength 0.14
  14. Antonia Malinova · 1 shared paper, 2023 · strength 0.14
  15. Jens Thomas Siveke · 1 shared paper, 2023 · strength 0.14
  16. Aldo Scarpa · 1 shared paper, 2023 · strength 0.14
  17. Daniel Öhlund · 1 shared paper, 2023 · strength 0.14
  18. Kim Pedersen · 1 shared paper, 2021 · strength 0.13
  19. Faiz Bilal · 1 shared paper, 2021 · strength 0.13
  20. Josep M. Tabernero · 1 shared paper, 2021 · strength 0.13
  21. Joaquı́n Arribas · 1 shared paper, 2021 · strength 0.13
  22. Teresa Mercade Macarulla · 1 shared paper, 2021 · strength 0.13
  23. Peter J. Bailey · 1 shared paper, 2017 · strength 0.05
  24. Julien Sage · 1 shared paper, 2017 · strength 0.05
  25. Naiara Perurena · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.